Blog
RSS FeedPosted by Michael Wonder on 16 Jan 2024
PHARMAC - 2023 in review
17 January 2024 - 2023 was yet another dismal year for New Zealanders in terms of them being able to ...
Posted by Michael Wonder on 16 Jan 2024
Ono Pharm’s Braftovi for BRAF V600E mutated colorectal cancer gets reimbursement
11 January 2024 - Ono Pharmaceutical Korea said Thursday that Braftovi (encorafenib), a targeted therapy for BRAF V600E mutated metastatic ...
Posted by Michael Wonder on 08 Jan 2024
'GSK's immunotherapy Jemperli paves way for second-line endometrial cancer treatment'
7 December 2023 - GSK's immunotherapy Jemperli (dostarlimab) is set to play a key role in the second-line treatment of ...
Posted by Michael Wonder on 05 Jan 2024
CVS will remove AbbVie's Humira from some drug reimbursement lists in April
4 January 2024 - CVS Health said on Wednesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some ...
Posted by Michael Wonder on 22 Dec 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) receive public listing for patients with advanced endometrial carcinoma that is not MSI-H or dMMR
21 December 2023 - Merck and Eisai announce that Keytruda plus Lenvima, is now reimbursed with clinical criteria and conditions ...
Posted by Michael Wonder on 21 Dec 2023
RemeGen announces continued inclusion of telitacicept and disitamab vedotin in China National Reimbursement Drug List, ensuring continuous accessibility of innovative drugs for more patients
18 December 2023 - RemeGen has recently confirmed that under the 2023 simple renewal mechanism of China National Healthcare Security ...
Posted by Michael Wonder on 18 Dec 2023
Zai Lab announces the first listing of Vyvgart (efgartigimod alfa) and other updates in China’s National Reimbursement Drug List
12 December 2023 - Zai Lab today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare ...
Posted by Michael Wonder on 14 Dec 2023
Antengene announces inclusion of Xpovio (selinexor) in 2023 China's National Reimbursement Drug List
13 December 2023 - Antengene today announced that Xpovio (selinexor) has been added to the National Reimbursement Drug List (2023 Version) ...
Posted by Michael Wonder on 13 Dec 2023
Hutchmed announces continued inclusion of Elunate (fruquintinib) and Sulanda (surufatinib) in the National Reimbursement Drug List in China at current terms
12 December 2023 - Hutchmed today announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration, ...
Posted by Michael Wonder on 09 Nov 2023
UnitedHealth unit to add eight insulin products to its reimbursement list
9 November 2023 - UnitedHealth's pharmacy benefit manager unit said on Thursday it was adding eight insulin products to its ...
Posted by Michael Wonder on 30 Oct 2023
Switzerland restricts reimbursement of orphan drugs
30 October 2023 - New rules for the reimbursement of orphan drugs and other unlisted medicines will become effective in Switzerland ...
Posted by Michael Wonder on 05 Aug 2023
Alarmed by popularity of Ozempic and Wegovy, insurers wage multi-front battle
3 August 2023 - Patients are bracing for “D-Day,” the date their insurance companies will stop covering the drugs. Doctors ...
Posted by Michael Wonder on 17 Jul 2023
Novel Alzheimer disease treatments and reconsideration of US pharmaceutical reimbursement policy
17 July 2023 - While donanemab appears to be among the first therapies to demonstrate measurable clinical benefit for Alzheimer's disease, ...
Posted by Michael Wonder on 18 Apr 2023
AbbVie announces provincial reimbursement for Vraylar (cariprazine) for the treatment of schizophrenia in Québec
17 April 2023 - AbbVie today announced that Vraylat is now listed as an exception medication status on the list of ...
Posted by Michael Wonder on 02 Apr 2023
Mitsubishi Tanabe Pharma Canada receives engagement letter from Pan-Canadian Pharmaceutical Alliance for Radicava oral suspension
31 March 2023 - Mitsubishi Tanabe Pharma Canada is pleased to announce the company has entered into negotiations with the ...